The integration of next-generation sequencing panels in the clinical cancer genetics practice: An institutional experience

Genetics in Medicine

Volumn 16, Issue 5, 2014, Pages 407-412

  Mauer, Caitlin B ^a   Pirzadeh Miller, Sara M ^a   Robinson, Linda D ^a   Euhus, David M ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

BRCA; genetic testing; genomics; next generation sequencing; panel testing

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; DNA;

ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER RISK; CLINICAL DECISION MAKING; COLON CANCER; FAMILIAL CANCER; GENE MUTATION; GENE SEQUENCE; GENETIC SCREENING; HEALTH CARE COST; HIGH RISK INFANT; HUMAN; MAJOR CLINICAL STUDY; NEXT GENERATION SEQUENCING; OVARY CANCER; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; DNA SEQUENCE; ECONOMICS; GENETIC COUNSELING; GENETICS; HIGH THROUGHPUT SEQUENCING; NEOPLASMS; PROCEDURES;

GENETIC COUNSELING; GENETIC TESTING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA;

EID: 84899974241     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2013.160     Document Type: Article

References (24)

1. Meder B, Haas J, Keller A, et al. Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet 2011;4:110-122.
2. Lin X, Tang W, Ahmad S, et al. Applications of targeted gene capture and nextgeneration sequencing technologies in studies of human deafness and other genetic disabilities. Hear Res 2012;288:67-76.
3. Ambry Genetics, 2013. Hereditary cancer panels. http://ambrygenetics.com/ next-gen-cancer-panels Accessed 1 July 2013.
4. Ambry Genetics, 2012. The case for clinical adoption of hereditary breast cancer panel testing. http://www.ambrygen.com/sites/default/files/pdfs/ cancer%20 forms/BreastNext-WhitePaper-100412.pdf Accessed 1 July 2013.
5. National Comprehensive Cancer Network, Inc., 2013. Genetic/Familial High- Risk Assessment: Breast and Ovarian, Version 2.2013. http://www.nccn.org/ professionals/physician-gls/pdf/genetics-screening.pdf Accessed 8 March 2013.
6. Pennington KP, Walsh T, Lee M, et al. BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma. Cancer 2013;119:332-338.
7. Walsh T, Casadei S, Coats KH, et al. Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 2006;295:1379-1388.
8. Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci USA 2011;108: 18032-18037.
9. Silvestri V, Rizzolo P, Falchetti M, et al. Mutation screening of RAD51C in male breast cancer patients. Breast Cancer Res 2011;13:404.
10. Loveday C, Turnbull C, Ruark E, et al.; Breast Cancer Susceptibility Collaboration (UK). Germline RAD51C mutations confer susceptibility to ovarian cancer. Nat Genet 2012;44:475-476; author reply 476.
11. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet 2010;42:410-414.
12. Ahmed M and Rahman N. ATM and breast cancer susceptibility. Hum Mutat 2006; 27:1122-1128.
13. Renwick A, Thompson D, Seal S, et al.; Breast Cancer Susceptibility Collaboration (UK). ATM mutations that cause ataxia-Telangiectasia are breast cancer susceptibility alleles. Nat Genet 2006;38:873-875.
14. Bernstein JL, Teraoka S, Southey MC, et al. Population-based estimates of breast cancer risks associated with ATM gene variants c.7271TG and c.1066- 6TG (IVS10-6TG) from the Breast Cancer Family Registry. Hum Mutat 2006;27:1122-1128.
15. Gutiérrez-Enríquez S, Fernet M, Dörk T, et al. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer 2004;40:109-119.
16. Mao JH, Wu D, DelRosario R, Castellanos A, Balmain A, Perez-Losada J. Atm heterozygosity does not increase tumor susceptibility to ionizing radiation alone or in a p53 heterozygous background. Oncogene 2008;27:6596-6600.
17. Angèle S, Falconer A, Edwards SM, et al. ATM polymorphisms as risk factors for prostate cancer development. Br J Cancer 2004;91:783-787.
18. CHEK2 Breast Cancer Case-Control Consortium. CHEK2. 1100delC and susceptibility to breast cancer: A collaborative analysis involving 10, 860 breast cancer cases and 9, 065 controls from 10 studies. Am J Hum Genet 2004;74:1175-1182.
19. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: Current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-1662.
20. Cybulski C, Wokolorczyk D, Huzarski T, et al. A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer. J Med Genet 2006;43:863-866.
21. Schröder FH, Hugosson J, Roobol MJ, et al.; ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-1328.
22. Cybulski C, Górski B, Huzarski T, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 2004;75:1131-1135.
23. Szymanska-Pasternak J, Szymanska A, Medrek K, et al. CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. Gynecol Oncol 2006;102:429-431.
24. Xiang HP, Geng XP, Ge WW, Li H. Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility. Eur J Cancer 2011;47:2546-2551.